Lilly/Innovent Experience Show Hurdles Remaining For Chinese PD-1 Inhibitors

 
• By Alaric DeArment
  
3d illustration of T cells attacking a cancer cell
ODAC voted 14-1 to recommend an additional trial for Lilly/Innovent PD-1 inhibitor sintilimab • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category